{"id":3179,"date":"2021-12-01T12:01:26","date_gmt":"2021-12-01T11:01:26","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=3179"},"modified":"2022-09-20T10:12:57","modified_gmt":"2022-09-20T08:12:57","slug":"neue-lipidsenker-teil-1-inclisiran-und-bempedoinsaeure","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2021\/neue-lipidsenker-teil-1-inclisiran-und-bempedoinsaeure","title":{"rendered":"Neue Lipidsenker Teil 1:  Inclisiran und Bempedoins\u00e4ure"},"content":{"rendered":"<p>Die Senkung erh\u00f6hter Blutfette mit dem Ziel, atheromat\u00f6se Gef\u00e4\u00dferkrankungen zu vermeiden, wird komplexer und teurer. Dies ist u.a. so, weil das Konzept \u201eTreat to target\u201c mit sehr niedrigen Zielvorgaben f\u00fcr den Surrogat-Endpunkt LDL-C (\u201ethe lower the better\u201c) in den Leitlinien wichtiger Fachgesellschaften und dank eines intensiven Marketings bei vielen \u00c4rzten verankert werden konnte (vgl. ). [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die Senkung erh\u00f6hter Blutfette mit dem Ziel, atheromat\u00f6se Gef\u00e4\u00dferkrankungen zu vermeiden, wird komplexer und teurer. Dies ist u.a. so, weil das Konzept \u201eTreat to target\u201c mit sehr niedrigen Zielvorgaben f\u00fcr den Surrogat-Endpunkt LDL-C (\u201ethe lower the better\u201c) in den Leitlinien wichtiger Fachgesellschaften und dank eines intensiven Marketings bei vielen \u00c4rzten verankert werden konnte (vgl. ). [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[684,495,60,1272,255,5497,1274,5634,5635,5636,5637,71,68,453,5638,498,456,257,65,5639,5640,56],"class_list":["post-3179","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-akutes-koronarsyndrom","tag-angina-pectoris","tag-apoplektischer-insult","tag-arteriosklerose","tag-arzneimittel","tag-bempedoinsaeure","tag-cholesterin","tag-clear-harmony-studie","tag-clear-serenity-studie","tag-clear-tranquility-studie","tag-clear-wisdom-studie","tag-herzinfarkt","tag-hirninfarkt","tag-hypercholesterinaemie","tag-inclisiran","tag-koronare-herzkrankheit","tag-lipidsenker","tag-medikamente","tag-myokardinfarkt","tag-orion-10-studie","tag-orion-11-studie","tag-schlaganfall"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/3179","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=3179"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/3179\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=3179"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=3179"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=3179"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}